![]() Patients must be infused via CIV injection and monitored until treatment is done. The treatment is also as not as simple as taking a pill. With that being said, there may still be concerns about the drug’s complicated method of action, which requires patients to stay in the hospital for up to 48-72 hours to be treated. Some of this is obviously due to hospitals having to prioritize COVID-19 patients, which may have slowed sales a bit. Since then things haven’t gotten much better with the drug average only about $1.5 million per quarter. In the first quarter of launch, the drug made an astonishingly low $1.6 million in sales. Despite being the first treatment to earn FDA approval for postpartum depression, the company’s star drug Zulresson hasn’t been nearly as successful as investors hoped. This drug acts fast by utilizing the GABAA receptors in patients, which is the major inhibitory signaling pathway of the brain and central nervous system and contributes significantly to regulating brain function. Zulresson, unlike other depression treatments, is proven to have fast-acting positive effects on its patients. Sage Therapeutics got off to a strong start with its drug Zulresson, which became the first treatment to get FDA approval for postpartum depression. ![]() However, he will have a very difficult task to take the company back to all-time highs. Greene was a natural fit with over 3 decades of experience in pharmaceutical management and since then the stock increased to a price of $75. In December last year, Sage Therapeutics announced its new CEO, Barry Greene would be taking over while the previous CEO would go into a research role. Even so, wit h recent lackluster phase 3 results from Zuranonlone, will the company be able to recover to all-time highs, or will it continue to disappoint investors? Since then, the company has made great strides to please investors changing its CEO and partnering with Biogen. In less than a year the company would plummet all the way to a low of $26 in April 2020. However, this victory was short-lived as the company suffered a failure in its trial for their second drug, SAGE-217. This news propelled stock all the way up to $190 in July 2019 and the company was looking to be at the forefront of treatments for depression. ![]() The drug was approved in March 2019 becoming the first and only drug approved for postpartum depression. The company made its debut with its drug Zulresso, for the treatment of postpartum depression in adults. Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies to treat central nervous system disorders.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |